What are the most common reasons for insomnia? What is effective for treating insomnia? Can you explain sleep hygiene? In Part 2 she answers these questions and so much more! Dr. Jade Wu is a licensed clinical psychologist, sleep researcher, and host of the Savvy Psychologist podcast. She is a frequent guest on popular radio and podcast shows such as NPR, and quoted in popular press publications like New York Times, NBC News, and Huffington Post. Her current research focuses on treating sleep disorders in those with chronic illness. In the clinic, Dr. Wu uses evidence-based non-medication treatments to help people improve their sleep (and wake). Her approach is grounded in both science and compassion, so that her clients are empowered to live healthier and more fulfilled lives.  My website: www.JadeWuPhD.com Twitter: @JadeWuPhD Resources can be found on her website under the "Resources" tab.

Join us for this important extended Q&A session with psychiatric nurse practitioner; Deb York, in which she answers your most pressing questions from her presentation on early life childhood adversity.

Join us for a fascinating extended Q&A with Dr. William Sauve’ where he addresses your unanswered questions from his presentation on the mental health consequences of COVID-19.

In this episode, listen in for an extended Q&A session with Dr. Jeffrey Strawn as he answers your most pressing questions from his presentation on treating refractory anxiety disorders.

In this exciting extended Q&A session, Dr. James Knoll addresses your unanswered questions from his presentation on Mass Shootings.

How do we know how much sleep we actually need? Are devices like the FitBit accurate at tracking what stage of sleep we’re in, according to heart rate? How does substance abuse contribute to nightmares? In this episode of the NEI Podcast, psychiatrist and sleep researcher, Dr. Jade Wu answers these questions and so much more! Learn about her cutting-edge research in Part 1 of this episode. Dr. Jade Wu is a licensed clinical psychologist, sleep researcher, and host of the Savvy Psychologist podcast. She is a frequent guest on popular radio and podcast shows such as NPR, and quoted in popular press publications like New York Times, NBC News, and Huffington Post. Her current research focuses on treating sleep disorders in those with chronic illness. In the clinic, Dr. Wu uses evidence-based non-medication treatments to help people improve their sleep (and wake). Her approach is grounded in both science and compassion, so that her clients are empowered to live healthier and more fulfilled lives.  My website: www.JadeWuPhD.com Twitter: @JadeWuPhD Resources can be found on her website under the "Resources" tab.

How are social media platforms being used for negativity and what can people do to protect their mental health on these platforms? How have you used Tiktok and other social media platforms to help remove the stigma associated with mental health conditions, and to make a positive impact in the adolescent population? In this episode, we interview psychiatric nurse practitioner, Dr. Sarfo Kojo on how he is using social media to create a positive impact on mental health. Dr. Kojo Sarfo, DNP, PMHNP-BC is a Ghanaian-American Psychiatric-Mental Health Nurse Practitioner, entrepreneur, and writer. He graduated from The University of West Alabama with his Associate’s Degree in Nursing and then obtained his Bachelor’s in Nursing from Western Governors University. He went on to obtain his Doctorate in Nursing Practice degree from Augusta University with a specialty in Psychiatry. He has three years of teaching experience as an adjunct faculty professor with the College of Nursing at his alma mater, Augusta University. He has a passion for treating and caring for persons with severe mental health conditions. He is also the CEO and Co-Founder of Abrantie & Signora, LLC, which is a clothing company dedicated to spreading positivity and mental health awareness for teenagers and college students. Dr. Sarfo has over 328,000 followers on TikTok. For more information on Dr. Sarfo: https://www.kojosarfo.com/ Dr. Sarfo’s Podcast: https://podcasts.apple.com/us/podcast/the-kojo-sarfo-podcast/id1477749374 Dr. Sarfo’s YouTube Channel: https://www.youtube.com/kojosarfo Dr. Sarfo’s Clothing Company: https://abrantiesignora.com/ Dr. Sarfo’s Book: https://www.amazon.com/You-Already-Won-Education-Awareness/dp/1692141805/ref=sr_1_1?dchild=1&keywords=dr.+kojo+sarfo&qid=1603218480&sr=8-1  

What is an ecological momentary assessment? How are ecological momentary interventions powerful and helpful in a clinical research setting? Learn more about how digital technology, smart phone applications, electronic surveys, and wearable devices can help in both the clinical research and the clinical treatment arena. In this fascinating interview with Dr. Katherine Houghton, she answers your most pressing questions about applying digital technology to capture real-world/real-time data, and to help patients at the most critical times. Katherine Houghton, Ph.D. is fascinated by the intersection of technology and psychology. She is actively engaged in designing and testing systems to facilitate positive behavior change in a variety of populations. She co-founded ilumivu in 2009 (ilumivu.com) to provide software systems to researchers and clinicians to capture human data and deliver just-in-time interventions. Ilumivu's first software service was for parents of children with autism to track symptom change and treatment use in an online HIPAA compliant, sharable platform. Since then ilumivu has provided web, mobile and wearable systems to researchers and clinicians working with a wide range of populations including substance abuse, suicide, anxiety and depression. They are committed to finding innovative and effective ways to use everyday technology to improve the daily life experience of the millions of people who suffer with mental health issues. *Optional*Kat is also very engaged in local environmental activism bringing Community Rights and the Rights of Nature to the City of Asheville through a nonprofit she co-founded, Community Roots (cmroots.com). She also leads wilderness Rites of Passage ceremonies to help people through challenging times. Resources: Ilumivu website: https://ilumivu.com/ Ilumivu Twitter: https://twitter.com/ilumivuTweets Kat's LinkedIn: https://www.linkedin.com/in/kathoughton/ Website to Kat's non-profit, Community Roots: https://www.cmroots.com/   Need to fulfill your CME credits? Join us virtually at NEI Max! and earn up to 28.75 CME credits. Check out with promo code PODCAST09 to get 10% off.  

Opioid addiction, abuse, and overdose have all grown to epidemic proportions in the United States as well as worldwide in recent years—such information is no longer up for debate. With an estimated 400,000 persons using illicit opiates each month, and another 4 million reporting use of prescription pain relievers for nonmedical purposes, in the United States alone, the debate now surrounds how best to treat those individuals suffering from opioid use disorder (OUD). In the past few years, there has been growing evidence for the efficacy of medication assisted therapy (MAT) for the treatment of OUD. However, there are still many challenges. Questions arise such as: What sort of training does a prescriber need to undertake in order to be able to prescribe medications for the treatment of OUD and how is this a barrier to treatment? How are the billing procedures for MAT challenging for clinicians who are prescribing? In this CME NEI Podcast, Dr. Larissa Mooney answers these questions and more on MAT for OUD. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Describe the challenges to treating opioid use disorder (OUD) with medication assisted therapy (MAT) Explore treatments designed to optimize cessation of opioid addiction Discuss legal barriers and insurance barriers to treatment of OUD  Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MDs and DOs: NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as “providers of formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Faculty Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Faculty Interviewer / Author Larissa J. Mooney, MD Associate Clinical Professor, Department of Psychiatry and Biobehavioral Sciences; Director, Addiction Medicine Clinic; University of California, Los Angeles Semel Institute for Neuroscience and Human Behavior, Los Angeles, CAChief, Substance Use Disorders Clinic, VA Greater Los Angeles Healthcare System, Los Angeles, CA No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported by an unrestricted educational grant from Alkermes.  Released: Sept 30, 2020          CME credit expires: Sept 30, 2023   Need to fulfill your CME credits? Join us virtually at NEI Max! and earn up to 28.75 CME credits. Check out with promo code PODCAST09 to get 10% off.

September is National Recovery Month! In this invigorating interview with addiction expert, Dr. Nzinga Harrison, we discuss the need for removing the stigma and misconceptions surrounding the topic of addiction, and how to apply treatment strategies focused on understanding compassion, and evidence-based scientific research. When it comes to addiction, there are many questions. What does it mean to say that someone is in recovery? What are some behavioral addictions that most people don’t think about? Are there such things as healthy addictions? In this episode, Dr. Harrison shares a refreshing and novel perspective on the topics of addiction and recovery. A well-respected physician and educator, Dr. Harrison is the host of the In Recovery weekly podcast by Lemonada Media, she engages a large audience on all things addiction with the goal of leading with compassion, evidence and reducing stigma.   She is Chief Medical Officer and Co-Founder of  Eleanor Health, an innovative company who provides comprehensive, longitudinal outpatient care for individuals experiencing opioid and other substance use disorders. She earned her Bachelor’s degree in Biology with Spanish and Chemistry minors at Howard University, completed medical school at the University of Pennsylvania School of Medicine and General Psychiatry Residency at Emory University.   She is Board-Certified in both Adult General Psychiatry and Addiction Medicine and has spent her career treating individuals with Serious Persistent Mental Illness and Addictive Diseases.  Currently, she holds adjunct faculty appointments at the Morehouse School of Medicine Department of Psychiatry is Co-Founder of Physicians for Criminal Justice Reform, Inc. and Campaign Psychiatrist for Let’s Get Mentally Fit, a public education and stigma-reduction campaign.   Resources: Dr. Nzinga Harrison’s In Recovery Podcast: https://www.lemonadamedia.com/show/in-recovery/ Eleanor Health: https://www.eleanorhealth.com/  

When it comes to serious mental illness (SMI), mental health professionals work hard to help remove the associated negative stigma, and to educate patients and caregivers to help them thrive. In this episode, we interview two clinical experts who are part of an interdisciplinary team at the APA/SMI Advisor program. This joint initiative between the American Psychiatric Association and the Substance Abuse and Mental Health Services Administration, or SAMSHA is an innovative clinical support program for clinicians, caregivers, and patients with serious mental illness.  In this episode, we discuss the topic of serious mental illness with two mental health experts, Dr. Donna Rolin and Dr. Joseph Ventura. We also discuss their upcoming joint-presentation at this year’s APNA, on the importance of incorporating the Basic Psychiatric Rating Scale (BPRS) into practice.   Donna Rolin, Ph.D. is Clinical Associate Professor and the Director of the Psychiatric Mental Health Nurse Practitioner program at the University of Texas with 23 years of experience in psychiatric nursing. She is co-leading inter-disciplinary graduate training initiatives with Schools of Nursing, Medicine, Educational Psychology, Social Work, and Pharmacy with funding from the Health Resources and Services Administration and the Texas Higher Education Coordinating Board aiming to expand a culturally diverse workforce for underserved populations. She serves as the Co-Director of the Institute for Domestic Violence and Sexual Assault (IDVSA), working alongside Schools of Social Work, Law and Bureau of Business Research. Dr. Rolin’s current research focuses on wellness self-management for mental health promotion and the integration of telepresence robots in healthcare education. Dr. Rolin serves on the national Board of Directors of the American Psychiatric Nurses Association and the local Board of the Directors of the Psychiatric Advanced Practice Nurses of Austin. Dr. Rolin continues her clinical practice as a Psychiatric Advanced Practice Registered Nurse with a community-based group working with underserved patients with serious mental illnesses (SMI), neurocognitive disorders, and intellectual disabilities in outpatient, long term care, telepsychiatry, and inpatient psychiatric facilities. She acts as the SMI Nursing Expert on the American Psychiatric Association’s Clinical Support Services for SMI (CSS-SMI) Clinical Expert Team. Joseph Ventura, Ph.D. is a Clinical Psychologist and Research Scientist with expertise in the assessment and treatment of individuals with serious mental illness. Dr. Ventura is the Director of Cognitive Training and Diagnosis and Symptom Assessment for the UCLA Aftercare Program. His areas of expertise include cognitive remediation, assessment of neurocognitive functioning, psychiatric diagnosis, symptom assessment, recovery from mental illness, and evaluation of functional outcomes in the early phase of schizophrenia. Dr. Ventura has led research funded by several agencies most notably the National Institute of Mental Health (NIMH) and the Brain and Behavior Foundation (formerly NARSAD). His research has concentrated on stressful life events, positive and negative symptoms, neurocognition, social cognition, cognitive training, and predictors of course and functional outcome. Dr. Ventura has played a major role in the development and publication of methods for standardizing diagnostic and symptom assessment training and for ongoing quality assurance. His recent work focuses on clinical correlates of the core features of serious mental illness, dimensions of social cognition, inflammatory biomarkers, the development of interview-based assessments of cognitive functioning, and factors that are associated with recovery from serious mental illness. Recently, he was awarded a US Fulbright Scholar Grant to develop a program promoting early assessment, identification, and prevention of mental illness in clinical high-risk populations in North Africa. Dr. Ventura has published widely in peer-reviewed journals, lectured extensively, and conducted numerous training workshops both nationally and internationally. UCLA Aftercare Program: The UCLA Aftercare Program (brochure attached) is a joint clinical and research program located in the UCLA Department of Psychiatry specializing in the treatment of people who are in the early phase of schizophrenia or a related psychotic disorder. For over 30 years, and through NIMH and industry funding, our Aftercare treatment team has been providing comprehensive services to schizophrenia patients most of whom are transitional age youth (late teens or early twenties). However, we can serve patients from age 18 to 45. Our primary treatment aim is to assist patients with symptomatic and functional recovery after experiencing a first psychotic episode or who are within 2 years of the first onset of psychotic symptoms.  The Aftercare program provides a comprehensive set of treatment services to eligible patients including regular visits with a psychiatrist, anti-psychotic medication (second generation), case management, various forms of psychosocial interventions including group and individual therapy, a cognitive training program that is in some cases boosted by an aerobic exercise program, family education and support, and transportation to UCLA. Our clinic psychiatrists are Laurie Casaus, M.D. and Margaret Distler, M.D. Additional Aftercare services include, supported employment and supported education programs, family therapy, and providing research updates to family members. We can provide all of these services for up to two years at no cost to the patient or family because we are funded.   The Aftercare clinic is headed by members of the UCLA Department of Psychiatry, Keith Nuechterlein, Ph.D., Kenneth Subotnik, Ph.D., Luana Turner, PsyD., Joseph Ventura, Ph.D, who have been providing these services through the Aftercare Program for many years to early course patients. Rebecca Zornitsky, MSc. is our Community Liaison Specialist along with Taylor Jester and Elaine Clarke. APA/SMI Adviser Site & Resources: https://smiadviser.org/ Clozapine Center of Excellence: https://smiadviser.org/about/clozapine Long-Acting Injectable (LAI) Antipsychotics Center of Excellence: https://smiadviser.org/about/lai How to download SMI Adviser App: Apple: https://apps.apple.com/us/app/smi-adviser/id1473024646 Google: https://play.google.com/store/apps/details?id=org.smiadviser&hl=es_PE How to download My Mental Health Crisis Plan (Psychiatric Advance Directive [PAD]) App Apple: https://apps.apple.com/us/app/my-mental-health-crisis-plan/id1497373282 Google: https://play.google.com/store/apps/details?id=org.smiadviser.apa&hl=en_US APNA Annual Meeting Presentation on Brief Psychiatric Rating Scale (BPRS) Annual Meeting 9/30 – 10/4/2020 (Virtual) https://www.apna.org/i4a/pages/index.cfm?pageid=3467 Presentation on BPRS – Dr. Joseph Ventura & Dr. Donna Rolin Thursday, 10/1 @5pm ET https://www.apna.org/i4a/pages/index.cfm?pageID=4595 2034: Advanced Practice 5:00pm ET - 5:45pm ET Using the Brief Psychiatric Rating Scale (BPRS) as a Symptom Assessment Tool in Measurement-Based Care – RN, APRN This interactive presentation teaches participants to rate psychiatric symptoms using a structured interview, the Brief Psychiatric Rating Scale. The goal is to build and/or expand assessment skills for rating initial symptom severity and for monitoring symptom change over time to improve quality of treatment within a measurement-based care approach.  Abstract Presenters: Joseph Ventura, PhD; Donna Rolin, PhD, APRN, PMHCNS-BC, PMHNP-BC  

Autism Spectrum Disorder (ASD) is highly comorbid with other psychiatric disorders, including attention deficit hyperactivity disorder (ADHD). Unfortunately, there may be many overlapping symptoms between ASD and ADHD that make it difficult to distinguish between these disorders. In this fascinating episode, Dr. David Goodman examines the history of autism, Asperger’s disorder, and how to differentiate between overlapping symptoms for ADHD. He also addresses how to treat these disorders concurrently. Dr. David W. Goodman is an assistant professor in the department of psychiatry and behavioral sciences at Johns Hopkins School of Medicine in Baltimore, and the director and founder of the Adult Attention Deficit Disorder Center of Maryland in Baltimore, MD. His interests include adult ADHD, associated mood/anxiety/substance use disorders, and complex psychopharmacology.

What specific issues do female nurse practitioners, or physicians treating mental health face in the workplace? What are some of the work-life issues that women face, when it comes to balancing a career in medicine with family? What are the research findings on sexual harassment toward women in the mental health profession? In this important episode, Dr. Christina Girgis addresses these questions, and more! Dr. Christina Girgis is a psychiatrist in the Hines, Illinois area, certified by both the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. She is currently the Medical Director of the Consultation-Liaison Psychiatry Service at Edward Hines, Jr. VA Hospital and the Associate Training Director of the Psychiatry Residency Program at Loyola University Medical Center. She is also the founder of Psychiatry Network, and several other professional Facebook groups. For more information please click on the link below: https://www.facebook.com/groups/psychnetwork/

Schizophrenia is a chronic and debilitating disorder that creates a substantial burden not only for patients but also for their families. The high rates of treatment resistance, relapse rates, and incidence of adverse side effects in patients with schizophrenia suggest that a major treatment gap continues to exist. Given the high rates of treatment resistance, novel strategies and therapeutic approaches beyond D2 receptor blockade are being intensively studied. What are some of these novel approaches? How effective are they in the treatment of schizophrenia? What medications are available, or emerging that target neurotransmitters systems beyond dopamine? In this podcast episode, Dr. Jonathan Meyer and Dr. Leslie Citrome discuss some of the ground-breaking work in this field, and how you can better treat patients with schizophrenia. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Describe clinical advances in our understanding of schizophrenia Describe novel treatments for schizophrenia Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee / Author Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, Vanda Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Lilly, Johnson & Johnson, Merck, Pfizer Interviewee / Author Jonathan M. Meyer, MD Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: Acadia, Alkermes, Allergan, Intra-Cellular Therapies, Neurocrine Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Neurocrine, Otsuka, Sunovion, Teva Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout. Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies. Released: July 23, 2020          CME credit expires: July 23, 2023

What are some of the difficulties that Muslim Americans face today, and what was the reason behind the creation of the Muslim Wellness Foundation? How does stigma about mental health problems uniquely impact the Muslim American community? What are some of the psychosocial issues and challenges that Black Muslim American's experience?  In this important and timely episode, psychiatrist Dr. Mona Masood answers these questions and so much more! As a member of the Board of Directors at the Muslim Wellness Foundation, Dr. Masood offers resources, shares exciting programs and ways to get involved with this movement.    For more information on the Muslim Wellness Foundation click on the link below:  https://www.muslimwellness.com/  

The years 2019-2020 brought to us coronavirus disease 2019 (COVID-19), resulting in an unprecedented global pandemic. Emerging data, historical studies, and expert opinion point to a tremendous impact of COVID-19 on the development and exacerbation of psychiatric issues. This issue is compounded by the fact that access to mental health care services may be limited during this time of crisis. There is a critical need for mental health care providers to be prepared and educated to best serve the psychiatric needs of patients affected, either directly or indirectly, by the COVID-19 pandemic. There are still many questions. What are the psychological consequences of so many people losing their jobs, and so many businesses shutting down? What are some healthy coping strategies for parents to model at home, to protect their children’s mental health during this pandemic? In this CME NEI podcast episode, Dr. McIntyre answers these questions, and much more.  Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE.  Learning Objectives: After completing this educational activity, you should be better able to: Discuss the psychological, economic, and sociological implications that COVID-19 has had on mental health Examine the impact of COVID-19 on a variety of mental health issues Explore existing and novel strategies for continuing mental health care during a global pandemic such as COVID-19 Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. Peer Review: The content was peer-reviewed by a PhD-PMHNP specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Faculty Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Faculty Interviewee / Author Roger S. McIntyre, MD, FRCPC   Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada Grant/Research: CIHR/GACD/Chinese National Natural Research Foundation, Stanley Medical Research Institute Consultant/Advisor: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda Speakers Bureau: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported by an unrestricted educational grant from Alkermes.  Released: July 9, 2020          CME credit expires: July 9, 2023  

What exactly is brain-derived neurotrophic factor, or BDNF? What is the relationship between neuroinflammation, BDNF, and depression? What are ways that we can naturally stimulate increases in BDNF? In this exciting interview, psychiatric nurse practitioner, Michelle Novella answers all these questions and more! Michele Novella, PMHNP-BC, PMHCNS-BC, is the owner and medical director of Star Psychiatric Healthcare, LLC, in Danbury, CT. She was educated at Fairfield University in Fairfield, CT, and received her Master's Degree in Adult Psychiatric Nursing from Yale University, graduating with high Honors. Additionally, Ms. Novella is an inductee into the Sigma Theta Tau International Honor Society and is an active member of the ANA, APNA, and CTAPRNS. She is also a past recipient of the American Cancer Society's prestigious "Excellence in Onocology" Nursing Award for the State of CT.  She is a national speaker for several pharmaceutical companies, including Takeda and Lundbeck.

Healthcare workers on the frontline, working to save patients with the COVID-19 virus, during this pandemic have been especially vulnerable to mental health consequences and trauma. In the early stages of the global shut-down, Dr. Mona Masood launched the Physician Support Line, a volunteer hotline to support physicians and healthcare providers who were on the frontlines, battling the virus, and the traumatic consequences of doing so, simultaneously. Doctors, nurses, EMTs and other health care workers have been under extremely stressful conditions, increased patient loads without necessary staffing, a lack of personal protective equipment (PPE), and overtime hours, placing them at high risk for contracting the virus themselves. Many have lost colleagues to the virus.  In this episode, learn what inspired her to create this hotline, what it has done for physicians, and how you can get involved. Dr. Mona Masood is board certified in general adult psychiatry and is an outpatient psychiatrist in the Ivyland, Pennsylvania area.  She is also the founder of the Physician Support Line and a Board Member of the nonprofit Muslim Wellness Foundation, which provides mental health educational services to the community. For more information on the Physician Support Line please go to: https://www.physiciansupportline.com/

Methamphetamine is an extremely serious problem in the United States, and it remains one of the most commonly misused stimulant drugs in the world. There are severe psychological, and medical consequences from methamphetamine misuse and abuse. This poses a particular challenge for clinicians treating patients for mental health conditions that are comorbid with substance use disorder (SUD). This is especially challenging when there are also interactions that can alter or influence psychiatric medications used to treat these patients. Questions such as the following arise: Given the high comorbidity of SUD with ADHD, how often should you check drug screens, and what is the threshold for discontinuing the stimulants if tests come back positive? In this podcast episode, Dr. William Sauve’ addresses these concerns, and much more. He also employs strategies to improve communication with patients about being transparent when it comes to using substances. Optional CME credits / certificate instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Manage the challenges associated with psychiatric treatment of conditions comorbid with substance use disorder Integrate psychiatric drug interactions with methamphetamine use Assess treatments approaches for conditions associated with long-term use of methamphetamines Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics.  Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Faculty Interviewer Andrew J. Cutler, MD   Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Alkermes, Allergan, Axsome, Biohaven, Intra-Cellular, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Tris   Consultant/Advisor: Acadia, AiCure, Alfasigma, Alkermes, Allergan, Avanir, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Takeda, Teva, Tris Speakers Bureau: Acadia, Alkermes, Allergan, Avanir, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Takeda, Teva, Tris Faculty Interviewee William M. Sauvé, MD Regional Medical Director, Greenbrook TMS NeuroHealth Centers, Virginia Speakers Bureau: Avanir  Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported solely by the provider, NEI.  Released: June 8, 2020          CME credit expires: June 8, 2023

What is the prevalence of bipolar disorder in the pediatric population and does this change, depending on age? What are important tips for recognizing hypomania in children, and diagnosing children with mixed depression? In this episode, we address these questions and more with pediatric psychiatrist, Dr. Manpreet Singh.  Dr. Singh is Associate Professor of Psychiatry and Behavioral Sciences at Stanford University, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders. She is the director of the Pediatric Mood Disorders Program and the Pediatric Emotion and Resilience Program at Stanford University. Dr. Singh earned her MD at Michigan State University and her MS at University of Michigan. She completed her combined residency training in Pediatrics, Psychiatry, and Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center. After two years of T32 postdoctoral training at Stanford’s Center for Interdisciplinary Brain Sciences Research, she joined the faculty in 2009. Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All of these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes. In her spare time, Dr. Singh enjoys traveling and hiking with her husband and three children, and avidly teaches Indian classical music. Her clinical handbook for the diagnosis and treatment of pediatric mood disorders can be found at the link below: https://appi.org/Products/Mood-Disorders/Clinical-Handbook-for-the-Diagnosis-and-Treatment?SearchText=clinical%20handboo&sku=37174

Healthcare disparities occur around the world, due to a complex, multifaceted situation that results from socioeconomic hardships, psychosocial stress, and cultural differences. In the United States, these disparities are often seen in minority communities, such as Hispanics and Black Americans. When a pandemic, such as COVID-19 occurs, it can expose these disparities in the most tragic ways. Current statistics surrounding healthcare disparities during the pandemic are staggering, suggesting that COVID-19 has disproportionately impacted the Black American community. In this important and timely interview with Dr. Napoleon Higgins, we address your most pressing questions on why this is occurring, and how awareness can improve this situation for future generations. Dr. Napoleon Higgins, Jr., is a psychiatrist in the Houston/Clear Lake City Area. He currently serves as Owner, CEO and President of Bay Pointe Behavioral Health Service, Inc., and South East Houston Research Group, Inc. He also practices as the Medical Director of Hold My Hand Residential Treatment Center. Dr. Higgins specializes in treating mental health disorders through medication management, psychotherapy and behavioral training.

Food and beverages interact with certain psychiatric medications to alter their pharmacokinetic properties, resulting in potentially unintended health outcomes. In this podcast episode, Dr. Rajnish Mago describes common food and beverages that interact with psychiatric medication and provides recommendations for avoiding unintended food-drug interactions. Optional CME credits / certificate instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE.  Learning Objectives: After completing this educational activity, you should be better able to: Describe the effects of food on the bioavailability of certain psychotropic medications Discuss current evidence of the brain-gut connection’s impact on mental health Describe the effects of vitamin C, caffeine, and grapefruit on the pharmacokinetics of certain psychotropic medications  Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics.  Peer Review: The content was peer-reviewed by a PharmD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Faculty Interviewer / Author Andrew J. Cutler, MD   Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Alkermes, Allergan, Axsome, Biohaven, Intra-Cellular, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Tris   Consultant/Advisor: Acadia, AiCure, Alfasigma, Alkermes, Allergan, Avanir, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Takeda, Teva, Tris Speakers Bureau: Acadia, Alkermes, Allergan, Avanir, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Takeda, Teva, Tris Faculty Interviewee / Author Rajnish Mago, MD Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Travel Expenses: Intas Pharmaceuticals (for Indian Psychiatric Association annual meeting) Stockholder: Johnson and Johnson  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported solely by the provider, NEI.  Released: May 11, 2020          CME credit expires: May 11, 2023    

With the recent COVID-19 pandemic, mental health concerns are on the rise. What do we know about the relationship between suicide risk and previous pandemics or natural disasters? How do we distinguish between behavior that seems like appropriate coping during this time and behavior that should raise a red flag? What are some protective factors against suicide, and how can we capitalize on these, especially during this challenging time?  Join us, as we interview the Chief Medical Officer of the American Foundation for Suicide Prevention (AFSP), Dr. Christine Moutier. Dr. Moutier knows the impact of suicide firsthand. After losing colleagues to suicide, she dedicated herself to fighting this leading cause of death. Throughout her career she has focused on fighting stigma related to mental health and help seeking. Training healthcare leaders, physicians, and advocacy groups, Dr. Moutier has sought to change the healthcare system’s approach to mental health, in order to optimize care for those suffering from mental health conditions. As a leader in the field of suicide prevention, Dr. Moutier joined AFSP in 2013, and has revitalized AFSP’s Education team, re-launched its Loss & Healing department, and expanded AFSP’s support to include those with lived experience of suicide. Moutier has authored articles and book chapters for publications such as the Journal of the American Medical Association, Academic Medicine, the American Journal of Psychiatry, the Journal of Clinical Psychiatry, Psychiatric Times, Depression and Anxiety, and Academic Psychiatry. She has testified before the U.S. Congress and spoken at the White House, she was the host of AFSP’s documentary on surviving suicide loss, The Journey, and has appeared as an expert in The New York Times, The Washington Post, Time magazine, The Economist, The Atlantic, the BBC, NBC, CNN, and other print and television outlets. You can follow Dr. Moutier on Twitter at @cmoutierMD. For more information on the AFSP please visit: afsp.org

What is the evidence that exercise is at least as effective as medications for the treatment of mental health disorders, such as depression? Can you share any research findings on the effects of exercise for patients with traumatic brain injury?  If you have questions like these, you won't want to miss this episode with psychiatrist and renowed author, Dr. John Ratey! Best selling author, John J. Ratey, MD, is an Associate Clinical Professor of Psychiatry at Harvard Medical School and an internationally recognized expert in Neuropsychiatry. He has published over 60 peer-reviewed articles, and 11 books published in 17 languages, including the groundbreaking ADD-ADHD “Driven to Distraction” series with Ned Hallowell, MD. With the publication of  "Spark-The Revolutionary New Science of Exercise and the Brain," Dr. Ratey has established himself as one of the world's foremost authorities on the brain-fitness connection.  His most recent book, “Go Wild” explores how we can achieve optimal physical and mental health by getting in touch with our caveman roots, and how we can “re-wild” our lives.   Recognized by his peers as one of the Best Doctors in America since 1997, Dr. Ratey was recently honored by the Massachusetts Psychiatric Society as "Outstanding Psychiatrist of the Year" for advancing the field. Dr. Ratey and his work are frequently profiled in the media, where he’s been featured on ABC, CBS, NBC, PBS and NPR, as well as in The New York Times, Newsweek, The Washington Post, US News and World Report, Men’s Health, and other national publications.

Given the recent COVID-19 virus pandemic, how is pediatric anxiety influenced by things like the media, parental attitudes, and the family environment? How effective is telepsychiatry for pediatric patients? If you have these types of questions you won't want to miss this timely and important interview with psychiatrist Dr. Jeffrey Strawn! In this episode, we discuss issues like effective communication strategies for parents during this time, and how to best meet the needs of pediatric patients with anxiety. Dr. Strawn is an Associate Professor of Psychiatry and Pediatrics at the University of Cincinnati and at Cincinnati Children’s Hospital. He directs the University of Cincinnati Anxiety Disorders Research Program. His ongoing research explores the pathophysiology and psychopharmacology of anxiety disorders, using functional neuroimaging and magnetic resonance spectroscopy. His research further aims to identify early predictors of treatment response in anxiety and to identify which patients may respond best to which specific treatments. In his clinical practice, he works with youth with anxiety disorders and with their parents and families. 

What is our current understanding of the gut-brain connection? What is the difference between the microbiome and microbiota? How is dysbyosis of the gut associated with certain psychiatric disorders? In this CME podcast, we address these questions and more in this captivating interview between Dr. Andrew J. Cutler and Dr. Roger S. McIntyre! Optional CME credits / certificate instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Explore the relationship between the brain-gut-microbiome axis and chronic inflammation Discuss current evidence of the brain-gut connection’s impact on mental health Consider potential implications of the gut-brain connection for the treatment of various mental illnesses Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Faculty Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Alkermes, Allergan, Axsome, Biohaven, Intra-Cellular, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Tris Consultant/Advisor: Acadia, AiCure, Alfasigma, Alkermes, Allergan, Avanir, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Takeda, Teva, Tris Speakers Bureau: Acadia, Alkermes, Allergan, Avanir, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Takeda, Teva, Tris Faculty Interviewee / Author Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada Grant/Research: CIHR/GACD/Chinese National Natural Research Foundation, Stanley Medical Research Institute Consultant/Advisor: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda Speakers Bureau: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout. Support: This activity is supported solely by the provider, NEI. Released: April 13, 2020          CME credit expires: April 13, 2023

How do you manage billing and insurance for telepsychiatry? What are some challenges to treating patients who may not be tech saavy? In part 2 of this episode, we address these questions and more, providing you with the most current information on the practical implications of telepsychiatry in our interview with psychiatric nurse practitioner, Michele Novella.  Michele Novella, PMHNP-BC, PMHCNS-BC, is the owner and medical director of Star Psychiatric Healthcare, LLC, in Danbury, CT. She was educated at Fairfield University in Fairfield, CT, and received her Master's Degree in Adult Psychiatric Nursing from Yale University, graduating with high Honors. Additionally, Ms. Novella is an inductee into the Sigma Theta Tau International Honor Society and is an active member of the ANA, APNA, and CTAPRNS. She is also a past recipient of the American Cancer Society's prestigious "Excellence in Onocology" Nursing Award for the State of CT.  She is a national speaker for several pharmaceutical companies, including Takeda and Lundbeck. Additional Resources:  Telepsychiatry Applications/Programs: Kareo: https://www.kareo.com/ Doxy.Me: https://doxy.me/ Zoom: https://zoom.us/ ICD-10-CM Official Coding Guidelines from the CDC: https://www.cdc.gov/nchs/data/icd/ICD-10-CM-Official-Coding-Gudance-Interim-Advice-coronavirus-feb-20-2020.pdf 

In this episode, we discuss the importance and practical implications of telepsychiatry in the field of mental health, with psychiatric nurse practioner, Michele Novella. Has your practice been impacted by the COVID-19 pandemic? In part 1 of this episode, Michele takes you step-by-step through the process of implementing telepsychiatry into your practice. Learn about the "do's" and "don'ts", and important information that you will need to know to better treat your patients during this challenging time!  Michele Novella, PMHNP-BC, PMHCNS-BC, is the owner and medical director of Star Psychiatric Healthcare, LLC, in Danbury, CT. She was educated at Fairfield University in Fairfield, CT, and received her Master's Degree in Adult Psychiatric Nursing from Yale University, graduating with high Honors. Additionally, Ms. Novella is an inductee into the Sigma Theta Tau International Honor Society and is an active member of the ANA, APNA, and CTAPRNS. She is also a past recipient of the American Cancer Society's prestigious "Excellence in Onocology" Nursing Award for the State of CT.  She is a national speaker for several pharmaceutical companies, including Takeda and Lundbeck. Additional Resources:  Telepsychiatry Applications/Programs: Kareo: https://www.kareo.com/ Doxy.Me: https://doxy.me/ Zoom: https://zoom.us/ ICD-10-CM Official Coding Guidelines from the CDC: https://www.cdc.gov/nchs/data/icd/ICD-10-CM-Official-Coding-Gudance-Interim-Advice-coronavirus-feb-20-2020.pdf 

In this episode, we raise awareness about a forgotten, yet extremely vulnerable population at high risk for traumatic brain injury (TBI). What are ways that we can better screen for patients who have experienced intimate partner violence (IPV)? How are types of brain injuries unique in this population? Are there neuroimaging techniques that can more accurately detect IPV-related TBIs?  Deb York is a board certified Psychiatric-Mental Health Nurse Practitioner practicing in Colorado Springs, CO.  She completed her research certification as a Certified Clinical Research Associate at the Association of Clinical Research Professionals. Deb has a clinical focus in endocrine psychiatry for the treatment of a variety of psychiatric illnesses with specialized expertise in treatments for mood disorders involving menopause, andropause, PMS, PMDD and post-partum depression.  Her research focuses on conducting clinical trials to identify and evaluate novel psychopharmacological and neuroradiological interventions for traumatic brain injury, mood disorders, and pediatric psychiatric illnesses. Additionally, Deb is certified in Bioidentical Hormone Replacement Therapy through the Academy for Preventive and Innovative Medicine by WorldLink Medical. Deb has over 25 years in the clinical trials industry conducting clinical research in pharmaceuticals & biologics, with a specialty in Women’s Health, CNS & psychiatric clinical trials. Deb completed her Bachelor of Science in Nursing at the University of Missouri-St. Louis Barnes College of Nursing-Washington University.  She completed her Master’s Degree at the University of Cincinnati in Nurse Midwifery and her Post-Master’s Certification from the University of Cincinnati in Psychiatry-Mental Health. Additionally, Deb is an Adjunct Professor at the College of Nursing at the University of Cincinnati and Director of Clinical Research at Mountain Mind.  

What are ketones and how are they related to mental health? What is the relationship between mitochondrial dysfunction and the ketogenic diet? What is the carnivore diet? If these are some of your questions when it comes to nutrition and mental health, you won't want to miss Part II of this exciting interview with Dr. William Sauve'!

Are carbohydrates bad for me? Is the ketogenic diet good for the brain? What is the carnivore diet? These are questions that concern many people today, especially if you're interested in nutrition and the brain. In Part I of this episode we dive into this hot topic with Dr. William Sauve', where we discuss many of these questions and more!   Dr. William M. Sauve' is a psychiatrist in Virginia. He received his medical degree from Uniformed Services University of the Health Sciences and has been in practice between 11-20 years.

In Part II of this interview with Dr. Rona Hu, we discuss the most effective ways of assessing and preventing violence in the healthcare setting. Learn how to protect yourself, how to cope with such experiences, and how to support one another in the aftermath. 

In this episode, we dive into a topic that is not talked about enough, yet many clinicians experience assault by patients. Here, we address how to identify risks, how to decrease escalation from agitation to aggression, and how to cope after a violent event has occurred with a patient. Dr. Rona Hu is the Associate Dean of Academic Affairs at Stanford University School of Medicine. She is a Clinical Professor at Stanford University, and she was the formal Medical Director of the Acute Psychiatric Unit at Stanford for 20 years.

In Part II of this episode, we continue to take a look back at 2019 with Dr. Andrew Cutler, as we reflect on the most FDA approvals, exciting research findings and all the important updates in psychopharmacology that could impact your practice.  Dr. Andrew Cutler is Chief Medical Officer (CMO) at the Neuroscience Education Institute (NEI). He has deeply rooted knowledge in clinical practice, academic experience, and emerging science in psychiatry through clinical trials. He is Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida. He has been the principal investigator on more than 400 psychiatric and medical clinical trials.

In this episode, we take a look back at 2019 with Dr. Andrew Cutler, as we reflect on the most FDA approvals, exciting research findings and all the important updates in psychopharmacology that could impact your practice.  Dr. Andrew Cutler is Chief Medical Officer (CMO) at the Neuroscience Education Institute (NEI). He has deeply rooted knowledge in clinical practice, academic experience, and emerging science in psychiatry through clinical trials. He is Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida. He has been the principal investigator on more than 400 psychiatric and medical clinical trials. Stay tuned for more exciting reflections from 2019, in Part II of this episode. 

Join Dr. Andy Cutler through this lightning-speed review of how to manage antipsychotic medications and treat psychosis. Tune in for the latest information from this year's Congress! 

In this episode, we interview Dr. Donna Wilcock, about her cutting-edge research on the role of inflammation, vascular impairment, and cerebrovascular disease on Alzheimer's disease! Dr. Donna Wilcock is a Professor of Physiology at the University of Kentucky and the Sanders-Brown Center on Aging.

In this fascinating extended Q&A session with Dr. Rona Hu, join us as she answers important questions about her presentation on the assessment and management of agitation!

Join us for this exciting extended Q&A session with Dr. Kari Franson, as she addresses your questions from her presentation on the legislation and legalization of marijuana and protecting your patients!

In this extended Q&A session with Dr. Andrew Cutler, we discuss your most important questions from his presentation on antipsychotic treatment approaches beyond the D2 receptor!

Join us for a fascinating extended Q&A with Dr. Leslie Citrome, where he answers your most pressing questions from his presentation on the assessment and treatment of eating disorders!

In this exciting extended Q&A session, Dr. William Sauve’ addresses some of your unanswered questions about his presentation on the current applications for the treatment of neuropsychiatric conditions with brain stimulation techniques!

In this episode, listen in for an extended Q&A session with Dr. Roger McIntyre as he answers some fascinating questions about his presentation on inflammation and depression: the gut-brain interaction!

Join us for this exciting extended Q&A session where Dr. Timothy Wilens addresses your most pressing questions from his presentation on transitioning from adolescence to adulthood with ADHD!

In this episode, we discuss the publishing process from the perspective of the Managing Editor of CNS Spectrums, Lisa Arrington. Learn how to avoid the most common mistakes in the submission process, and how to let your submission stand out! Lisa Arrington is Managing Editor for CNS Spectrums at Cambridge University Press. Check out the scientific poster session for CNS Abstracts at this year’s NEI Congress 2019. Saturday evening, November 9th!

Did you know that 20% of hospitalizations for adverse drug events are caused by drug interactions? In this episode, we talk to Dr. Patrick Finley, an expert in drug interactions and pharmacokinetics. Learn about the major factors that affect or alter the pharmacokinetic stages of drug metabolism. Explore more about cytochrome P450s and why they’re important when it comes to prescribing. Learn what drugs inhibit or induce these enzymes, and what the current research is on how to adjust drug dosage, according to genetic testing. Do you want to be able to fine-tune your approach to prescribing medications, to develop more individualized treatment approaches for your patients? Then you won’t want to miss this episode! Dr. Patrick Finley is a Professor of Clinical Pharmacy at the University of California, San Francisco. He is also a board-certified psychiatric pharmacist and has been a licensed medical provider for the last 15 years.  Resources:  Comprehensive Cytochrome P450 table with References: www.medicine.iupui.edu/flockhart/    QTc prolongation: www.crediblemeds.org  EBM review of herbs and supplements: www.naturalstandard.com  International Pharmacogenetics Consortium: www.pharmgkb.org/   

In this episode, we go behind the scenes of this year’s annual American Psychiatric Nurses Association (APNA) meeting and interview Dr. Mary Moller on a presentation she will be jointly delivering with Dr. Kate Wheeler, titled “A Third Nervous System? Lions and Tigers and Bears, Oh My!” We discuss how to incorporate the polyvagal theory of trauma into practice and how to effectively treat patients who have experienced trauma. Learn how a better understanding of the way the mammalian nervous system has evolved, may empower patients to transition from a more primitive freezing response, to becoming more active and socially engaged, thus resulting in enhanced healing. Dr. Mary D. Moller, DNP, ARNP, PMHCNS-BC, CPRP, FAAN is an advanced registered nurse practitioner who is dually certified as a clinical specialist in adult psychiatric-mental health nursing and a psychiatric rehabilitation practitioner. She is an Associate Professor at Pacific Lutheran University in Tacoma, WA where she is Lead Faculty for the Undergraduate Psychiatric Nursing Program and coordinator for the development of a Doctor of Nursing Practice program for psychiatric-mental health nursing. She is also the Director of Psychiatric Services for Northwest Center for Integrated Health in Tacoma, WA where she is in practice as a psychiatric ARNP treating patients in a triple integration agency: substance abuse, mental illness, and primary care. Resources: Book by Stephen W. Porges: “Clinical Applications of the Polyvagal Theory: The Emergence of Polyvagal Therapies”: https://www.amazon.com/Clinical-Applications-Polyvagal-Theory-Polyvagal-Informed/dp/1324000503/ref=sr_1_5?keywords=Stephen+Porges&qid=1570048266&sr=8-5  “The Pocket Guide to the Polyvagal Theory: The Transformative Power of Feeling Safe”: https://www.amazon.com/Pocket-Guide-Polyvagal-Theory-Transformative/dp/0393707873/ref=sr_1_3?keywords=Stephen+Porges&qid=1570048328&sr=8-3 Application of polyvagal theory in therapy: “The Polyvagal Theory in Therapy” by Deb Dana: https://www.amazon.com/Polyvagal-Theory-Therapy-Interpersonal-Neurobiology/dp/0393712370/ref=sr_1_1_sspa?keywords=Stephen+Porges&qid=1570048328&sr=8-1-spons&psc=1&spLa=ZW5jcnlwdGVkUXVhbGlmaWVyPUEzVlhPQUM4SkpSUDBCJmVuY3J5cHRlZElkPUEwMTc4MTU2MVBWUDJIWUNCSFNTMyZlbmNyeXB0ZWRBZElkPUEwODk5Nzk2MVVFR1FNVDJUM0tUUiZ3aWRnZXROYW1lPXNwX2F0ZiZhY3Rpb249Y2xpY2tSZWRpcmVjdCZkb05vdExvZ0NsaWNrPXRydWU=  Books by Joseph LeDoux: “Anxious” https://www.amazon.com/Anxious-Using-Brain-Understand-Anxiety/dp/0143109049/ref=sr_1_2?keywords=joseph+ledoux&qid=1570048552&sr=8-2 

Adult Deficit Hyperactivity Disorder (ADHD) is a life-long disorder that may not be diagnosed until much later in life. Symptoms of distraction, forgetfulness, and procrastination become confused with normal aging, yet may cause a significant disturbance to the quality of life in these patients. In this episode, we interview Dr. David Goodman, an expert on adult ADHD about how to effectively manage ADHD in the older population. We discuss hidden challenges, and the most effective approach for accurate diagnosis. Dr. Goodman is an assistant professor in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine and the director and founder of the Adult Attention Deficit Disorder Center of Maryland in Baltimore, MD.  Resources: David W. Goodman, M.D., LFAPA, http://www.addadult.com National Public Radio interview with Dr. David Goodman on Older Adults with ADHD, https://www.npr.org/sections/health-shots/2016/01/18/462978127/cant-focus-it-might-be-undiagnosed-adult-adhd Psychiatric Times podcast with Dr. David Goodman on Older Adults with ADHD, https://www.psychiatrictimes.com/adhd/adhd-older-adults